Iclusig® (ponatinib) our first approved medicine

A remarkable place doing remarkable work

We're looking for people who want to make a difference for cancer patients

OPEN POSITIONS

A unique, highly targeted approach to cancer

Our research & development program

LEARN MORE

NEWS & FEATURES

Latest News

2/2/16
ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2015 Financial Results
Read More
2/1/16
ARIAD Announces FDA Clearance to Begin Clinical Development of AP32788
Read More

TWITTER FEED